Over the past 20 years, a great deal of effort has been directed towards increasing our knowledge of the clinical pharmacology of digoxin and other cardiac glycosides. This has been made possible by the application of isotopic tracer techniques, employing 14C and 3H labelled glycosides, and by the development of assay methods which are capable of measuring small concentrations of digoxin in biological fluids, notably the plasma. Numerous articles on various aspects of the clinical pharmacology of digoxin have been published and most doctors now accept that the therapeutic range of plasma digoxin concentration lies between 1 and 2 ng/ml (1 3 and 2 5 nmol/l) and that knowledge of the plasma concentration may provide a useful guideline in the adjustment of therapy. Whether or not the plasma digoxin concentration is useful in the diagnosis of digoxin toxicity is still a matter of debate (Ingelfinger and Goldman, 1976) .
Irrespective of the value of plasma digoxin measurements, much of the work to establish a scientific basis for digoxin therapy has shown the importance of certain characteristics of individual patients; the relation between dose, kinetic behaviour of the drug, and its clinical effect has been 'Present address: Age Research Unit, University of Newcastle upon Tyne, 20 Framlington Place, Newcastle upon Tyne. Received for publication 4 April 1977 8 shown to depend upon important factors such as age, sex, body weight, and renal function (Jelliffe, 1967; Kolendorf et al., 1972; Wagner, 1974; Koup et al., 1975; Sumner et al., 1976) . These factors have been incorporated into computer programmes designed to calculate drug dosage schedules to suit individual patients (Jelliffe et al., 1972; Peck et al., 1973; Sheiner et al., 1975; Mawer, 1976) and into relatively simple prescribing aids in the form of nomograms (Jelliffe and Brooker, 1974) and formulae (Dobbs et al., 1976; Sumner et al., 1976) .
As digoxin therapy in older patients is known to be associated with a number of problems, including the development of toxicity and the question of its long-term usefulness, we decided to investigate the effect of current knowledge of the clinical pharmacology of digoxin on its use in this age group and selected for this purpose a representative group of elderly patients in hospital.
Patients and methods
A group of 42 elderly patients receiving maintenance digoxin therapy was studied over a three-month period. The patients were drawn from acute assessment wards, rehabilitation units, or long-term care wards in the Glasgow Northern Group of hospitals. In accordance with the policy of this Group, all patients were receiving the same brand of digoxm (Lanoxin, Burroughs Wellcome).
After selection of a patient for inclusion in the study, predose ('trough') and 6-hour postdose plasma digoxin concentrations were measured by radioimmunoassay, and a careful record was made of the patient's drug history. Age, sex, weight, a measure of renal function based on at least two serum creatinine estimations, and details of previous digoxin therapy were entered into a computer programme provided by Professor G. E. Mawer of the University of Manchester. This was designed to calculate drug dosage to suit individual patients and to predict corresponding plasma digoxin concentrations at specific times in relation to a dose, viz. predose ('trough') and 6-hours postdose. The programme was of the 'fixed model' type, the rationale of which has been described recently by Mawer (1976 The effect of any change in treatment was assessed 3 to 4 weeks later by clinical examination and by further estimations of trough and 6-hour plasma digoxin concentrations. Even when no change was made, digoxin levels were also measured after a 3-to 4-week period.
In many patients who were not incontinent, creatinine clearance was calculated, using either a 6-or a 24-hour urine collection, and this value was compared with corresponding creatinine clearances predicted by the programme.
Results
Of the 42 patients, 9 were men, aged 70 to 91 years (mean 78 years) and 33 were women, aged 64 to 90 years (mean 77-3 years). All were receiving maintenance digoxin for the treatment of congestive cardiac failure and/or atrial fibrillation. The concomitant use of other drugs was almost universal, and included diuretics, potassium supplements, hypnotics, antibiotics, haematinics, and analgesics. On entry to the study, the daily digoxin dose ('initial dose') ranged from 0-0625 mg to 0*5 mg in four dose categories, viz, 0-0625 mg, 0 125 mg, 0'25 mg, and 0 5 mg. The commonest daily dose was 0-25 mg (43% of patients) while 29 per cent were taking 0-125 mg daily and 26 per cent 0-0625 mg daily; only one patient was taking 05 mg daily.
On the basis of both the comparison between actual and predicted data and clinical examination on entry to the study, the patients were divided into the 4 groups shown in the Table. Creatinine clearance* (measured) (ml/min) Creatinine clearance* (predicted) (mil/min) 41-6 ±17-4 37-3 ±11 Results are expressed as mean ± SD.
*No significant difference between measured and predicted creatinine clearance in 21 patients (paired t test). tDifference in initial dose between groups 3 and 4 is significant. P < 0-001 (t test). *Difference in final dose between groups 3 and 4 is not statistically significant.
GROUP 1
Sixteen patients (38%) required no change in digoxin dosage, which was satisfactory and conformed to that recommended by the programme (Fig. 1) . Actual trough and 6-hour plasma digoxin concentrations were spread throughout the subtherapeutic and therapeutic range and were similar to but slightly less than those predicted on the basis of the drug history (Fig. 2) . The clinical condition of this group of patients was satisfactory. With no change in prescribed treatment, a significant rise in both trough and 6-hour levels (P < 0.001) was seen when plasma digoxin concentrations were remeasured after a period of 3 to 4 weeks (Fig. 3) , and at this time, though there were some discrepancies, actual trough and 6-hour levels were similar to those predicted (Fig. 2) .
GROUP 2
Six patients (14%) had initial plasma digoxin concentrations well below the therapeutic range associated with predicted concentrations which were also subtherapeutic (Fig. 2) Ten patients (24%) had high initial plasma digoxin concentrations (Fig. 4 ) which were associated with inappropriately high doses (mean 0O264 mg daily) when compared with those recommended by the programme (mean 0 161 mg daily). Fig. 1 shows the initial doses and those recommended by the programme, which were subsequently adopted. The effect of this reduction in dosage on plasma digoxin concentrations can be seen in Fig. 4 , which also shows the good agreement between actual and predicted levels. The therapeutic range had obviously been achieved when plasma digoxin concentrations were measured again 3 to 4 weeks after the change in dosage. Seven patients in this group had typical extracardiac symptoms of digoxin toxicity including anorexia, nausea, and vomiting. These symptoms subsided completely on reduction of dosage. One patient with a trough level of 3 nmol/l and a 6-hour level of 3-9 nmol/I also had evidence of cardiac toxicity in the form of multifocal ventricular and supraventricular extrasystoles; after reduction in digoxin dosage, the supraventricular extrasystoles were abolished and the frequency of ventricular extrasystoles considerably reduced. The other 3 patients in this group showed no signs of digoxin toxicity but had high plasma digoxin concentrations and doses in excess of those recommended by the programme. concentrations ('actual') and levels predicted by the computer programme ( predicted') in patients who required a reduction (group 3) or an increase (group 4) in dosage. Vertical bars represent mean ± SD. P values are based on the paired t test.
GROUP 4
Ten patients (24%) had low initial plasma digoxin concentrations (Fig. 4 ) which were associated with inappropriately low doses (mean 0-081 mg daily) when compared with those recommended by the programme (mean 0-153 mg daily). Fig. 1 shows the initial doses and those recommended by the programme, which were subsequently adopted. The effect of this increase in dosage on plasma digoxin concentrations can be seen in Fig. 4 . Whereas a significant difference existed between actual and predicted 6-hour levels initially (P < 0 005), there was good agreement between actual and predicted levels after increase in dosage, and in most patients a therapeutic level was achieved. Actual trough levels at this time, however, were significantly less than those predicted (P < 0.025). Only one patient, who showed no signs of digoxin toxicity, had a subnormal potassium level (3 3 mmol/l, normal range 3-5 to 5*5 mmol/l) initially.
On the basis of clinical examination and measurement of T3 and T4 levels, all patients were euthyroid.
Discussion
This study was designed to assess the effect of recent advances in the clinical pharmacology of digoxin on the use of this drug in clinical practice. A group of elderly patients was chosen because of the particular problems encountered in this age group, notably toxicity. Many studies have highlighted the dangers of digoxin therapy in the elderly and Dall (1970) has shown that the drug can be stopped without detriment in a large proportion of elderly patients. Digoxin, therefore, has a certain 'nuisance value' which is related to its narrow therapeutic ratio and to doubts about its long-term effectiveness. As it is eliminated primarily by glomerular filtration, renal function is an important determinant of dosage and the importance of this in the treatment of elderly patients was shown quite clearly in the present study by the low creatinine clearance values, obtained both by direct measurement and by computer prediction. A mean (predicted) value of 35-6 ±13-7 (SD) ml/min for the whole group highlighted the inevitable deterioration in renal function which is associated with advancing age (Watkin and Shock, 1955) and which is explainable on the basis of Bricker's 'intact nephron hypothesis' (Bricker et al., 1960) . The adjustments in dose required in groups 3 and 4 were related principally to renal function in these groups, and the slightly higher creatinine clearance values in group 1 accounted for correspondingly higher doses. As the creatinine clearance is the individual patient characteristic which relates most closely to digoxin dosage requirement (Dobbs et al., 1976) Dall (1970) . Perhaps a more positive attitude is required towards withdrawing digoxin when there is doubt about the need for the drug in individual patients.
The dosage recommendations made by the programme made it obvious that a considerable number of patients were receiving doses inconsistent with their age, sex, body weight, and renal function. Patients in group 3 were receiving an inappropriately high dose while patients in groups 2 and 4 were receiving an inadequate dose. The reasons for this are probably complex but may include alterations in renal function with advancing age or intercurrent disease which would effectively reduce the elimination of digoxin. On the other hand, an overconservative attitude towards the prescribing of digoxin would impose inappropriate limitations on dosage; indeed, a twofold increase in dosage was required to achieve satisfactory control of cardiac failure or to improve the control of atrial fibrillation in patients who were inadequately dosed. It is interesting to note that the traditional 'geriatric' daily dose of 0-0625 mg was employed in 11 patients (26%) on entry to the study, but that subsequently no patient received such a small dose. The computer programme permitted a degree of control over dosage which is not normally practised, but which is feasible by simple manipulation of standard digoxin preparations as shown in Fig. 1 .
Throughout the four groups, there was relatively good agreement between actual and predicted levels, but this was subject to some interesting variation. Slight discrepancies may have been the result of an inability of the programme to recognise variations in digoxin bioavailability from one patient to another; a relatively uniform degree of digoxin absorption was assumed, viz. 60 per cent for 'Lanoxin' tablets (Huffman et al., 1974; Johnson and Bye, 1975) , which is not entirely realistic in practice. Individual differences in absorption, dis-tribution, and extrarenal elimination may also have accounted for the relatively large standard deviations associated with measured plasma digoxin concentrations. The discrepancies also reflected another important source of variation which was most noticeable in those patients not requiring any change in therapy. Fig. 3 shows that actual (measured) levels of plasma digoxin rose significantly without any apparent change in dosage over the period covered by the study, and there is no doubt that improved compliance contributed to this, even within a hospital setting. A recent study (Wandless and Davie, 1977) in a similar group of elderly patients in hospital has shown that compliance is by no means perfect. The present kind of study can, however, increase the interest of both patients and nursing staff in control of digoxin therapy to effect some improvement in compliance.
There seems no doubt that an individualised approach to digoxin therapy is desirable and that benefit can only result from a review of existing treatment in individual patients. Such a review can be facilitated by the measurement of plasma digoxin concentration and by revision of dosage regimens in the light of individual patient characteristics, notably renal function. Computational facilities need not be available, but use of simple prescribing aids, such as the formula illustrated above which relates the maintenance dose to the desired plasma concentration and total digoxin clearance, would help to prevent many of the errors which occur as a result of intuitive prescribing.
